Across TCGA pan-cancer cohorts, FAM174B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM174B data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FAM174B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM174B expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

LUAD, PDAC, and UCEC are the cancer types where FAM174B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.426	0.754	.013	20	view →
PDAC	DFS	Tertile	All	0.864	0.720	.034	3	view →
UCEC	DFS	Quartile	All	1.000	0.863	.036	2	view →
LSCC	DFS	Median	III,IV	1.000	0.551	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: FAM174B tumor-vs-normal RNA expression · all FAM174B data types